CN1330349C - Chinese medicine composition for treating urethra infection and preparing method - Google Patents
Chinese medicine composition for treating urethra infection and preparing method Download PDFInfo
- Publication number
- CN1330349C CN1330349C CNB2005101280602A CN200510128060A CN1330349C CN 1330349 C CN1330349 C CN 1330349C CN B2005101280602 A CNB2005101280602 A CN B2005101280602A CN 200510128060 A CN200510128060 A CN 200510128060A CN 1330349 C CN1330349 C CN 1330349C
- Authority
- CN
- China
- Prior art keywords
- weight portion
- herba
- rhizoma
- water
- poria
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims abstract description 60
- 238000000034 method Methods 0.000 title claims abstract description 38
- 239000000203 mixture Substances 0.000 title claims description 21
- 208000015181 infectious disease Diseases 0.000 title description 4
- 210000003708 urethra Anatomy 0.000 title description 2
- 238000002360 preparation method Methods 0.000 claims abstract description 27
- 239000002994 raw material Substances 0.000 claims abstract description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 108
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 94
- 239000009636 Huang Qi Substances 0.000 claims description 57
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 57
- 235000008504 concentrate Nutrition 0.000 claims description 33
- 239000012141 concentrate Substances 0.000 claims description 33
- 239000007788 liquid Substances 0.000 claims description 33
- 238000010992 reflux Methods 0.000 claims description 27
- 238000012546 transfer Methods 0.000 claims description 26
- 238000002481 ethanol extraction Methods 0.000 claims description 25
- 239000012567 medical material Substances 0.000 claims description 25
- 238000011282 treatment Methods 0.000 claims description 18
- 208000019206 urinary tract infection Diseases 0.000 claims description 17
- 239000008187 granular material Substances 0.000 claims description 11
- 239000006188 syrup Substances 0.000 claims description 7
- 235000020357 syrup Nutrition 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 229940098465 tincture Drugs 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 241001529739 Prunella <angiosperm> Species 0.000 claims 1
- 239000006196 drop Substances 0.000 claims 1
- 239000006210 lotion Substances 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 239000003826 tablet Substances 0.000 claims 1
- -1 tincture Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 12
- 208000000143 urethritis Diseases 0.000 abstract description 4
- 239000000126 substance Substances 0.000 abstract 2
- 235000003205 Smilax rotundifolia Nutrition 0.000 abstract 1
- 240000009022 Smilax rotundifolia Species 0.000 abstract 1
- 229940079593 drug Drugs 0.000 description 17
- 241000894006 Bacteria Species 0.000 description 16
- 210000002700 urine Anatomy 0.000 description 12
- 230000000844 anti-bacterial effect Effects 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 8
- 238000001035 drying Methods 0.000 description 8
- 238000002156 mixing Methods 0.000 description 8
- 241000191967 Staphylococcus aureus Species 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 241000588724 Escherichia coli Species 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 238000012856 packing Methods 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 239000008215 water for injection Substances 0.000 description 5
- 229920001353 Dextrin Polymers 0.000 description 4
- 239000004375 Dextrin Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 208000004880 Polyuria Diseases 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 235000019425 dextrin Nutrition 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000027939 micturition Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 206010018612 Gonorrhoea Diseases 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 230000002421 anti-septic effect Effects 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000007908 dry granulation Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 208000001786 gonorrhea Diseases 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 206010025482 malaise Diseases 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 230000001954 sterilising effect Effects 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 210000003932 urinary bladder Anatomy 0.000 description 3
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 description 2
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 229960003942 amphotericin b Drugs 0.000 description 2
- 230000003385 bacteriostatic effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000003907 kidney function Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 150000007660 quinolones Chemical class 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 2
- 229940013618 stevioside Drugs 0.000 description 2
- 235000019202 steviosides Nutrition 0.000 description 2
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- GSDSWSVVBLHKDQ-UHFFFAOYSA-N 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid Chemical compound FC1=CC(C(C(C(O)=O)=C2)=O)=C3N2C(C)COC3=C1N1CCN(C)CC1 GSDSWSVVBLHKDQ-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 201000004538 Bacteriuria Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- DNYGXMICFMACRA-XHEDQWPISA-N Gentamicin C2b Chemical compound O1[C@H](CNC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N DNYGXMICFMACRA-XHEDQWPISA-N 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 244000179560 Prunella vulgaris Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 235000009392 Vitis Nutrition 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 229960003022 amoxicillin Drugs 0.000 description 1
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 229940098166 bactrim Drugs 0.000 description 1
- 235000015278 beef Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229960002588 cefradine Drugs 0.000 description 1
- 229960001668 cefuroxime Drugs 0.000 description 1
- JFPVXVDWJQMJEE-IZRZKJBUSA-N cefuroxime Chemical compound N([C@@H]1C(N2C(=C(COC(N)=O)CS[C@@H]21)C(O)=O)=O)C(=O)\C(=N/OC)C1=CC=CO1 JFPVXVDWJQMJEE-IZRZKJBUSA-N 0.000 description 1
- RDLPVSKMFDYCOR-UEKVPHQBSA-N cephradine Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C)C(O)=O)=CCC=CC1 RDLPVSKMFDYCOR-UEKVPHQBSA-N 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 238000005485 electric heating Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- DNYGXMICFMACRA-UHFFFAOYSA-N gentamicin C1A Natural products O1C(CNC)CCC(N)C1OC1C(O)C(OC2C(C(NC)C(C)(O)CO2)O)C(N)CC1N DNYGXMICFMACRA-UHFFFAOYSA-N 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 208000020426 gonococcal urethritis Diseases 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229960004744 micronomicin Drugs 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229960000808 netilmicin Drugs 0.000 description 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 1
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 1
- 229960000564 nitrofurantoin Drugs 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 239000006916 nutrient agar Substances 0.000 description 1
- 229960001699 ofloxacin Drugs 0.000 description 1
- 238000009400 out breeding Methods 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229960002292 piperacillin Drugs 0.000 description 1
- IVBHGBMCVLDMKU-GXNBUGAJSA-N piperacillin Chemical compound O=C1C(=O)N(CC)CCN1C(=O)N[C@H](C=1C=CC=CC=1)C(=O)N[C@@H]1C(=O)N2[C@@H](C(O)=O)C(C)(C)S[C@@H]21 IVBHGBMCVLDMKU-GXNBUGAJSA-N 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940081561 rocephin Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- JLKIGFTWXXRPMT-UHFFFAOYSA-N sulphamethoxazole Chemical compound O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1 JLKIGFTWXXRPMT-UHFFFAOYSA-N 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- KTAVBOYXMBQFGR-MAODNAKNSA-J tetrasodium;(6r,7r)-7-[[(2z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyimino-1-oxidoethylidene]amino]-3-[(2-methyl-5,6-dioxo-1h-1,2,4-triazin-3-yl)sulfanylmethyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate;heptahydrate Chemical compound O.O.O.O.O.O.O.[Na+].[Na+].[Na+].[Na+].S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C([O-])=NN1C.S([C@@H]1[C@@H](C(N1C=1C([O-])=O)=O)NC(=O)\C(=N/OC)C=2N=C(N)SC=2)CC=1CSC1=NC(=O)C([O-])=NN1C KTAVBOYXMBQFGR-MAODNAKNSA-J 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 210000001113 umbilicus Anatomy 0.000 description 1
- 201000002327 urinary tract obstruction Diseases 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Antibacterial | Preparation of the present invention | Positive control drug | Normal saline |
Staphylococcus aureus | 13.6±1.1 | 12.7±1.1 | 0 |
Staphylococcus albus | 12.8±0.7 | 13.5±1.0 | 0 |
First is paid Bacillus typhi | 13.0±1.1 | 11.9±1.1 | 0 |
Second is paid Bacillus typhi | 14.6±1.6 | 12.5±1.3 | 0 |
Pay cold bar bar | 13.3±0.8 | 12.7±1.0 | 0 |
Escherichia coli | 14.0±1.1 | 14.1±1.4 | 0 |
Strain | Drug dilution concentration (the g crude drug/ml) | MIC (the g crude drug/ml) | ||||||||||
1∶1 | 1∶2 | 1∶4 | 1∶8 | 1∶16 | 1∶32 | 1∶64 | 1∶128 | 1∶256 | 1∶512 | NS | ||
Gold Portugal bacterium | - | - | + | + | + | + | + | + | + | + | + | 0.7013 |
White Portugal bacterium | - | - | + | + | + | + | + | + | + | + | + | 0.7013 |
First is paid Bacillus typhi | - | - | + | + | + | + | + | + | + | + | + | 0.7013 |
Second is paid Bacillus typhi | - | - | - | + | + | + | + | + | + | + | + | 0.3506 |
Bacillus typhi | - | - | - | - | + | + | + | + | + | + | + | 0.1753 |
Escherichia coli | - | - | + | + | + | + | + | + | + | + | + | 0.7013 |
Strain | Drug dilution concentration (g/m) | MIC (the g content/ml) | ||||||||||
1∶1 | 1∶2 | 1∶4 | 1∶8 | 1∶16 | 1∶32 | 1∶64 | 1∶128 | 1∶256 | 1∶512 | NS | ||
Gold Portugal bacterium | - | - | + | + | + | + | + | + | + | + | + | 0.0625 |
White Portugal bacterium | - | - | - | + | + | + | + | + | + | + | + | 0.0313 |
First is paid Bacillus typhi | - | - | - | + | + | + | + | + | + | + | + | 0.0313 |
Second is paid Bacillus typhi | - | - | + | + | + | + | + | + | + | + | + | 0.0625 |
Bacillus typhi | - | - | + | + | + | + | + | + | + | + | + | 0.0625 |
Escherichia coli | - | - | + | + | + | + | + | + | + | + | + | 0.0625 |
Medicine | Number of animals (only) | Death toll (only) | Mortality rate (%) | |||
24h | 48h | 72h | 7 days dead altogether | 5.0 | ||
Blank group | 20 | 1 | 1 | |||
Normal saline | 20 | 15 | 2 | 17 | 85.0 | |
Blood stasis of prostatic gland dredging | 20 | 3 | 4 | 2 | 10 | 50.0 * |
Small dose group | 20 | 8 | 3 | 2 | 13 | 65.0 |
Middle dosage group | 20 | 3 | 3 | 2 | 9 | 45.0 * |
Heavy dose of group | 20 | 3 | 4 | 1 | 8 | 40.0 ** |
Claims (7)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005101280602A CN1330349C (en) | 2005-11-25 | 2005-11-25 | Chinese medicine composition for treating urethra infection and preparing method |
HK06113691A HK1092725A1 (en) | 2005-11-25 | 2006-12-13 | Chinese medicine composition for treating urinary tract infection and its preparing method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2005101280602A CN1330349C (en) | 2005-11-25 | 2005-11-25 | Chinese medicine composition for treating urethra infection and preparing method |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1814221A CN1814221A (en) | 2006-08-09 |
CN1330349C true CN1330349C (en) | 2007-08-08 |
Family
ID=36906653
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2005101280602A Active CN1330349C (en) | 2005-11-25 | 2005-11-25 | Chinese medicine composition for treating urethra infection and preparing method |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN1330349C (en) |
HK (1) | HK1092725A1 (en) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104208356A (en) * | 2014-09-26 | 2014-12-17 | 禤燕华 | Chinese medicinal composition for treating urethral diseases |
CN104324201A (en) * | 2014-11-18 | 2015-02-04 | 郝建友 | Traditional Chinese medicine preparation for treating urinary system infection and production method |
CN104474390B (en) * | 2014-11-19 | 2018-09-11 | 王小龙 | A kind of Chinese medicine for treating overactive bladder and palindromic urinary tract infection |
CN105596462A (en) * | 2016-01-22 | 2016-05-25 | 章雪妮 | Traditional Chinese medicine preparation for treating urinary system infection and preparation method and application thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1174075A (en) * | 1997-07-12 | 1998-02-25 | 迟经惠 | Medicine for arteriosclerosis |
CN1284349A (en) * | 2000-03-20 | 2001-02-21 | 范永昌 | Medicine pill for preventing and treating pathological seaility |
-
2005
- 2005-11-25 CN CNB2005101280602A patent/CN1330349C/en active Active
-
2006
- 2006-12-13 HK HK06113691A patent/HK1092725A1/en not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1174075A (en) * | 1997-07-12 | 1998-02-25 | 迟经惠 | Medicine for arteriosclerosis |
CN1284349A (en) * | 2000-03-20 | 2001-02-21 | 范永昌 | Medicine pill for preventing and treating pathological seaility |
Also Published As
Publication number | Publication date |
---|---|
CN1814221A (en) | 2006-08-09 |
HK1092725A1 (en) | 2007-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101314004B (en) | Medicament for treating gynaecologic urinary system infection contamination and preparation method thereof | |
CN102225127B (en) | Traditional Chinese medicine composite for treating mastitis of dairy cattle | |
CN1330349C (en) | Chinese medicine composition for treating urethra infection and preparing method | |
CN100500176C (en) | Chinese medicine composition with functions of expelling surficial evils and clearing away heat and toxic materials and its preparing method and application | |
CN102755563B (en) | Traditional Chinese medicine composition for treating chronic prostatitis and preparation method thereof | |
CN102579622B (en) | Chinese herbal preparation for treating haemophilusparasuis and preparation method thereof | |
CN101618051B (en) | Novel medicinal use of active parts of abelmoschus manihot general flavones | |
CN108339032A (en) | A kind of traditional Chinese medicine for oral administration Pu Jin treating mastitis for milk cows is scattered | |
CN101366898B (en) | Gynopathy treating traditional Chinese medicine composition and method of preparing the same | |
CN101401903B (en) | Chinese medicinal composition for treating endometritis of cow | |
CN101953981A (en) | Chinese medicinal preparation for treating stranguria caused by overstrain | |
CN104337901A (en) | Chinese medicinal preparation for treating nonspecific cystitis and preparation method thereof | |
CN1970020B (en) | A pharmaceutical composition, preparation process and application thereof | |
CN101209315A (en) | Chinese medicinal injection with antimicrobial and anti-inflammation, milk-smoothing and mass-dissipating efficacy | |
CN109010557A (en) | A kind of preparation method and applications of Chinese medical extract that treating yellowish leukorrhea and heat gonorrhea gynecological disease | |
CN102670807A (en) | Medicine composition for treating prostatitis and preparation method and application thereof | |
CN104055981B (en) | One kind treats bronchiectasic Chinese medicine composition | |
CN103860695B (en) | A kind of Chinese medicine composition and preparation method for the treatment of pyretic stranguria syndrome of dampness-heat in lower jiao | |
CN109125427B (en) | Penyanjing suppository and preparation method thereof | |
CN103735903B (en) | One is antibacterial presses down stone Chinese medicine composition and preparation method thereof | |
CN101352489B (en) | Chinese medicine for treating acute tonsillitis and preparation method thereof | |
CN102091263B (en) | Application of Chinese medicine composition in preparation of medicament for treating overhigh level of urine cell factor or receptor thereof and Escherichia coli infection | |
CN102198191B (en) | Quick acting medicine for treating prostate and urinary system infections, and production process thereof | |
CN101461850A (en) | Application of Chinese medicinal composition in preparing medicament for treating acne | |
Pushkala et al. | Antimicrobial Activity of Siddha Formulations against Uropathogens |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1092725 Country of ref document: HK |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20211215 Address after: 276006 No. 209 Hongqi Road, Shandong, Linyi Patentee after: LUNAN HOPE PHARMACEUTICAL Co.,Ltd. Address before: 276005 No. 209 Hongqi Road, Shandong, Linyi Patentee before: LUNAN PHARMACEUTICAL Group Corp. |
|
TR01 | Transfer of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: The invention relates to a traditional Chinese medicine composition for treating urinary tract infection and a preparation method thereof Effective date of registration: 20211228 Granted publication date: 20070808 Pledgee: China Construction Bank Corporation Linyi Shizhong sub branch Pledgor: LUNAN HOPE PHARMACEUTICAL Co.,Ltd. Registration number: Y2021980016801 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20230331 Granted publication date: 20070808 Pledgee: China Construction Bank Corporation Linyi Shizhong sub branch Pledgor: LUNAN HOPE PHARMACEUTICAL Co.,Ltd. Registration number: Y2021980016801 |